CLINICAL TRIALS PROFILE FOR IOBENGUANE I-131

All Clinical Trials for IOBENGUANE I-131

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00126412 ↗	Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma	Completed	GE Healthcare	Phase 3	2005-08-02	The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.
NCT00126425 ↗	Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease	Completed	GE Healthcare	Phase 3	2005-07-01	The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcomes in subjects with heart failure and in comparison to subjects without cardiovascular disease.
NCT00126438 ↗	Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease	Completed	GE Healthcare	Phase 3	2005-07-01	The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcome in subjects with heart failure and in comparison to subjects without cardiovascular disease.
NCT00339131 ↗	ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid	Completed	Molecular Insight Pharmaceuticals, Inc.	Phase 1	2006-06-01	The purpose of this study is to test the safety of a drug called Ultratrace iobenguane I 131 that has radioactivity, to measure how long it takes for the drug to be absorbed and passed out of the body, and to measure how much radioactivity is absorbed into different tissues of the body.
NCT00458952 ↗	Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma	Completed	Molecular Insight Pharmaceuticals, Inc.	Phase 1/Phase 2	2007-04-01	The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.
NCT00659984 ↗	N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma	Completed	Molecular Insight Pharmaceuticals, Inc.	Phase 2	2008-06-01	RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIBG), may carry radiation directly to tumor cells and not harm normal cells. A bone marrow or peripheral stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by I 131 MIBG. PURPOSE: This phase II trial is studying the side effects and best dose of iodine I 131 MIBG followed by a stem cell transplant in treating young patients with relapsed or refractory high-risk neuroblastoma.

Clinical Trial Conditions for IOBENGUANE I-131

Condition Name

Condition Name for IOBENGUANE I-131
Intervention	Trials
Neuroblastoma	7
Pheochromocytoma	4
Paraganglioma	3
Ganglioneuroblastoma	3

Condition MeSH

Condition MeSH for IOBENGUANE I-131
Intervention	Trials
Neuroblastoma	9
Heart Failure	4
Pheochromocytoma	4
Ganglioneuroblastoma	3

Clinical Trial Locations for IOBENGUANE I-131

Trials by Country

Trials by Country for IOBENGUANE I-131
Location	Trials
United States	120
Canada	6
Puerto Rico	1

Trials by US State

Trials by US State for IOBENGUANE I-131
Location	Trials
Texas	7
Pennsylvania	7
North Carolina	7
Ohio	6
Illinois	6

Clinical Trial Progress for IOBENGUANE I-131

Clinical Trial Phase

Clinical Trial Phase for IOBENGUANE I-131
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	4
Phase 2	3

Clinical Trial Status

Clinical Trial Status for IOBENGUANE I-131
Clinical Trial Phase	Trials
Completed	9
Recruiting	3
Approved for marketing	2

Clinical Trial Sponsors for IOBENGUANE I-131

Sponsor Name

Sponsor Name for IOBENGUANE I-131
Sponsor	Trials
Molecular Insight Pharmaceuticals, Inc.	5
National Cancer Institute (NCI)	5
GE Healthcare	5

Sponsor Type

Sponsor Type for IOBENGUANE I-131
Sponsor	Trials
Industry	13
Other	6
NIH	5